Navigation Links
New line of approach for combination therapy against melanoma
Date:7/23/2012

​A melanoma is a malignant form of skin cancer and is one of the most aggressive types of tumors there is. Treatment is particularly difficult, because melanomas are usually resistant against conventional chemotherapy treatments. Agnieszka Gembarska and Chris Marine

(VIB/KU Leuven) have found a new line of approach in which to treat these aggressive skin cancers, namely by combating the interaction between the protein MDM4 and the tumor suppressor p53. Their research offers a new angle for the development of medication and confirms that combination therapies including those using the recently developed BRAF inhibitors hold the promise of further improvement of the clinical response to a treatment. This study was published in the authoritative journal Nature Medicine and will undoubtedly be followed with interest by the pharmaceutical industry.

Chris Marine: "Our results are important on two levels. From a scientific perspective, it is very important that we have been able to prove that p53 plays a key role in the formation of melanomas. However, this research also offers perspectives for optimizing the existing treatment strategies for melanomas. The current treatment with BRAF inhibitors has positive effects on nearly 80% of the patients, but many of them relapse after a few months. We may have discovered a way of preventing this relapse".

p53, MDM4 and the formation of cancer

Chris Marine and his team has a long standing interest in p53 - a master tumor suppressor protein (in other words a protein that counteract the formation of cancer). Mutations in the p53 gene are very common in many various types of cancer. Surprisingly, mutations in p53 are (almost) never seen in melanomas. Scientists suspected that melanomas had found an alternative way of bypassing the action of p53.

The protein MDM4 has a negative effect on the action of p53 and has been the scientific focus of the VIB investigators for many years. Agnieszka Gembarska and Chris Marine have now demonstrated that (65% of) melanomas contain much higher concentrations of the MDM4 protein than normal cells. The scientists found a pharmacological way to inhibit the interaction between MDM4 and p53 and were thereby able to restore the tumor suppressive effect of p53 in melanoma cells.

Chris Marine: "The restoration of the p53 activity in the melanoma cells makes these cells more susceptible to chemotherapy and the BRAF inhibitors. In our research, we were able to identify MDM4 as a very promising target for treatment of melanoma, as part of a combination therapy.


'/>"/>
Contact: Jean-Christophe Marine
JeanChristophe.Marine@cme.vib-kuleuven.be
32-497-405-476
VIB (the Flanders Institute for Biotechnology)
Source:Eurekalert

Related biology news :

1. Stanford scientists develop gene therapy approach to grow blood vessels in ischemic limbs
2. A project to research biological and chemical aspects of microalgae to fuel approach
3. UofL research holds promise of therapeutic approach for gum disease
4. Approach to diabetes self-management too narrow, study suggests
5. Manatee hearing good enough to sense approaching motorboats
6. Scripps Florida scientist awarded $1.5 million to design therapeutics with new RNA approach
7. New approach to spell checking gene sequences
8. Powerful new approach to attack flu virus
9. Potential new approach to regenerating skeletal muscle tissue
10. Bugs have key role in farming approach to storing CO2 emissions
11. Computing advances vital to sustainability efforts; new report recommends problem-focused, iterative approach to research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2017)... May 23, 2017  Hunova, the first robotic gym for the rehabilitation ... officially launched in Genoa, Italy . The first 30 ... and the USA . The technology was developed and ... by the IIT spin-off Movendo Technology thanks to a 10 million euro ... Release, please click: ...
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):
(Date:10/9/2017)...  BioTech Holdings announced today identification and patenting ... stem cell therapy prevents limb loss in animal ... that treatment with ProCell resulted in more than ... to standard bone marrow stem cell administration.  Interestingly, ... of therapeutic effect.  ...
(Date:10/9/2017)... ... October 09, 2017 , ... At its national board ... Stubbs, a professor in Harvard University’s Departments of Physics and Astronomy, has been selected ... member of the winning team for the 2015 Breakthrough Prize in Fundamental physics for ...
(Date:10/9/2017)... Antonio, Texas (PRWEB) , ... ... ... new study published on October 5, 2017, in the medical journal, Epilepsia, ... equivalence with the gold standard, video EEG, in detecting generalized tonic-clonic seizures ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... technologies, launched its ProxiMeta™ Hi-C metagenome deconvolution product, featuring the first commercially ... cloud-based bioinformatics software to perform Hi-C metagenome deconvolution using their own facilities, ...
Breaking Biology Technology: